Evaluating enzyme replacement therapies for Anderson-Fabry disease: commentary on a recent report

Anderson-Fabry disease (AFD) is a rare lysosomal storage disorder. Randomized controlled clinical trials (RCTs) are preferred as the highest category of evidence, but limited availability of robust evidence in rare diseases may necessitate the use of less rigorous evidence. An analysis of cohort stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Giugliani, Roberto, Westwood, Stephanie, Wellhoefer, Hartmann, Schenk, Jörn, Gurevich, Andrey, Kampmann, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Genética 2018
Materias:
Human and Medical Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6415596/
https://www.ncbi.nlm.nih.gov/pubmed/30334566
http://dx.doi.org/10.1590/1678-4685-GMB-2017-0345
Descripción
Sumario:Anderson-Fabry disease (AFD) is a rare lysosomal storage disorder. Randomized controlled clinical trials (RCTs) are preferred as the highest category of evidence, but limited availability of robust evidence in rare diseases may necessitate the use of less rigorous evidence. An analysis of cohort studies of enzyme replacement therapies for AFD published in 2017 by El Dib and coworkers made treatment recommendations that contradict previously published findings from RCTs and a systematic Cochrane review. Our commentary outlines concerns regarding selection criteria and statistical methods with their analysis.

Ejemplares similares